You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)八款產品商業化 總產品收入近14億人幣
阿思達克 08-08 17:06
信達生物(01801.HK)公布,今年第二季共有八款產品實現商業化,取得總產品收入近14億元人民幣(下同),按年增長逾35%,營銷產出和效率持續提升。這主要受惠於產品組合整體銷量的持續擴大,包括達伯舒(信迪利單抗注射液)強勁的銷售表現,疫情對次季銷售活動的影響亦已消散。 公司指,已建立起一條擁有涵蓋癌症、代謝、自身免疫、眼科及其他主要治療領域的逾30款新藥品種的創新產品管線。目前公司已取得九款產品獲批,2個品種在國家藥品監督管理局(NMPA)審評中,6個新藥分子進入3期或關鍵性臨床研究,另外還有約20個新藥品種已進入臨床研究。公司相信,其豐厚多元化的創新管線資產具有廣闊的市場潛力,為公司長期全球創新業務發展提供堅實基礎。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account